7946 IVANHOE AVENUE, LA JOLLA, CA
Other Events
Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Amended material disclosure
Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing, Investor Presentation
Departure of COO Jeffrey Millard at Ensysce Biosciences
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Reports First Quarter 2026 Financial Results
Q2
Q1
Q3
FY 2024
Notice of Exempt Offering of Securities
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Submission Upload
Correspondence